Affimed (NASDAQ:AFMD) Shares Cross Below 50 Day Moving Average – What’s Next?

Shares of Affimed (NASDAQ:AFMD) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.42 and traded as low as $1.31. Affimed shares last traded at $1.32, with a volume of 278,795 shares.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Wells Fargo & Company lowered their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Affimed in a research note on Tuesday, December 10th. Finally, Stifel Nicolaus lowered their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Affimed currently has an average rating of “Moderate Buy” and an average target price of $13.50.

Affimed Trading Down 2.9 %

The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average of $2.42 and a two-hundred day moving average of $3.59.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AFMD. FMR LLC raised its stake in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Choreo LLC purchased a new stake in shares of Affimed in the second quarter worth $54,000. Intellectus Partners LLC raised its position in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the period. Jane Street Group LLC purchased a new position in shares of Affimed during the 3rd quarter valued at $44,000. Finally, Point72 Asset Management L.P. boosted its holdings in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares during the period. 30.82% of the stock is currently owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.